Cite
Pembrolizumab‐associated chronic rhinosinusitis: A new endotype and management considerations.
MLA
Standiford, Taylor C., et al. “Pembrolizumab‐associated Chronic Rhinosinusitis: A New Endotype and Management Considerations.” International Forum of Allergy & Rhinology, vol. 13, no. 12, Dec. 2023, pp. 2248–51. EBSCOhost, https://doi.org/10.1002/alr.23213.
APA
Standiford, T. C., Patel, N. N., Singh, A., Gochman, G., Jamie Wu, T., Daud, A. I., & Goldberg, A. N. (2023). Pembrolizumab‐associated chronic rhinosinusitis: A new endotype and management considerations. International Forum of Allergy & Rhinology, 13(12), 2248–2251. https://doi.org/10.1002/alr.23213
Chicago
Standiford, Taylor C., Neil N. Patel, Amritpal Singh, Grant Gochman, Tara Jamie Wu, Adil I. Daud, and Andrew N. Goldberg. 2023. “Pembrolizumab‐associated Chronic Rhinosinusitis: A New Endotype and Management Considerations.” International Forum of Allergy & Rhinology 13 (12): 2248–51. doi:10.1002/alr.23213.